Celyad SA (CYAD.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Celyad Announces Pricing Of 47.3 Million Dollars Global Offering
- BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update
- BRIEF-Celyad Successfully Administers CYAD-01 In First Patients In Shrink And Link Trials
- BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient
- BRIEF-Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting